Document:

exhibit04_b11.htm - Generated by SEC Publisher for SEC Filing

  

 

 

EXHIBIT 4.(b)(11)

São Paulo, August 8th, 2016

 

To
Casino, Guichard-Perrachon 
148, rue de l’Université
75007 Paris

 

Attn: Jean-Charles Naouri

 

RE: Project Delphes – Commitment letter

 

Dear Sirs,

 

We hereby inform you that, on this date, the Board of Directors of Companhia Brasileira de Distribuição (“Company”) has unanimously resolved that the Company (i) shall cause its voting rights to be exercised at any shareholders meeting of Cnova N.V. (“Cnova”) in favor of the reorganization between Via Varejo S.A. and the Brazilian subsidiary of Cnova, Cnova Comércio Eletrônico S.A., as agreed under Reorganization Agreement; and (ii) will not tender any of its Cnova shares, held directly or indirectly, in the cash tender offers that Casino, Guichard-Perrachon has undertaken to launch for the ordinary shares of Cnova upon completion of the reorganization (the “Tender Offers”), nor to dispose of or transfer, directly or indirectly, Shares in any other manner or through any other instrument, in particular any derivative instruments, until the end of the Tender Offers. CBD will stand alongside and cooperate with CGP in the subsequent squeeze-out procedure, if any, aimed at having Casino obtain the shares of the remaining Cnova minority shareholders, for the avoidance of doubt excluding CBD shares.

 

Finally, we reiterate our agreement to all the terms of the letter agreement that CGP and CBD have executed, whereby CGP takes certain commitments vis-à-vis CBD in relation to their future relationships as shareholders of Cnova.

 

Yours sincerely,

 

/s/ Ronaldo Iabrudi                               

 

Companhia Brasileira de Distribuição
Ronaldo Iabrudi
Chief Executive OfficerConfidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.	 	Exhibit 10.6	 

 

First Amendment

 

to

License Agreement

 

This Amendment is made as of and effective from Dec. 5, 2016 (“Effective
Date”)

 

between

 

Argos Therapeutics, Inc.

(hereinafter “Argos”)

 

- and -

 

Lummy (Hong Kong) Co., Ltd.

(hereinafter “China Company”)

 

WHEREAS, Argos and China Company entered into a license agreement
dated April 7, 2015 (the “License Agreement”);

 

WHEREAS, the original License Agreement provided for technology transfer
of Argos’ Automated Systems for manufacture of AGS-003 and now the parties would like to further include technology transfer
of Argos’ manual method for manufacturing AGS-003 to China Company;

 

WHEREAS, Argos holds a non-exclusive royalty-bearing license dated
April 1, 2012 from the University of Antwerp and Gerold Schuler to [**] with the right to grant sublicenses (“Antwerp
License”), and China Company wishes to obtain such sublicense; AND

 

WHEREAS the parties now require that the Agreement be amended as
set forth herein,

the parties agree to amend the Agreement as follows:

 

 

		1.	In Article 1 (“Definitions”), the following Sections 1.103 to 1.104 are added:

 

1.103 “Antwerp China Patent Rights” means [**] and any reissues,
re-examinations or extensions thereof, excluding [**].

1.104 “Manual Method” means the same or substantially similar
method used to manufacture AGS-003 for Argos’ ADAPT trial, without use of the Automated Systems.

1.105 “Research Technology Transfer” means the training of selected
China Company personnel in research techniques and procedures at the Argos facility for the following Argos protocols: [**].

 

		2.	The following Section 2.6 is added to Article 2 (“Licenses”):

 

     

     

    

 

2.1.6 Argos hereby grants China Company a non-exclusive and royalty-bearing
sublicense under Antwerp China Patent Rights for the sole purpose of Developing, Manufacturing and Commercializing the Licensed
Products in the Field in the China Company Territory. Such sublicense is subordinate to the terms and conditions of the Antwerp
License. China Company shall pay to Argos, and Argos shall pass through to the University of Antwerp all fees and royalties due
under the Antwerp License in connection with its use of the Antwerp China Patent Rights. China Company agrees to comply with the
terms of the Antwerp License, including but not limited to reporting requirements.

 

 

		3.	The following Section 3.2.1.1 shall be inserted after Section 3.2.1:

 

3.2.1.1 Pass-through royalties and fees payable by China Company under the
sublicense of the Antwerp China Patent Rights. Making, offering for sale, selling or importing a Licensed Product made by the
Manual Method requires a sublicense from Argos under the Antwerp License in cases where a Licensed Product or manufacture thereof
would, absent the sublicense granted hereunder, infringe Antwerp China Patent Rights. China Company will pay to Argos, and Argos
will pass through, all fees due to the University of Antwerp under section 5.1(b, c and d) of Antwerp License in connection with
China Company’s activities in China Company Territory. Such payments shall be in addition to any amounts due to Argos under
the License Agreement, and the Recoupment Threshold will not apply. The obligation to pay these pass-through royalties and other
fees under such sublicense will cease upon expiration of the Antwerp China Patent Rights.

 

 

 

 

     

     

    

 

		4.	Section 3.3 is amended to read in its entirety as follows:

 

3.3       Milestones.
Subject to the terms and conditions of this Agreement, China Company shall make the non-refundable, non-creditable milestone payments
to Argos set forth below no later than [**] days after the earliest date on which the corresponding milestone event has first been
achieved with respect to a Licensed Product.

 

	Milestone Event	Milestone 

Payment
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]
	[**]	[**]

 

[**].

 

The following shall be deemed to be material breaches of this
Agreement, subject, however to the notice and cure period set forth in 10.2.l(a): (a) the Milestone Event set forth in (i) above
is not completed within [**] months after the Trigger Event, (b) the Milestone Event set forth in (ii) above is not completed within
[**] months after the Trigger Event, or (c) the Milestone Event set forth in (v) above is not completed within [**] months after
the Trigger Event, and, in each case, the failure to complete the applicable Milestone Event is not directly related to acts or
omissions by Argos. In addition, failure to achieve the following shall be deemed to be material breaches of this Agreement: (i)
within [**] months of the first [**] U.S. FDA approvals obtained by Argos for a Licensed Product, China Company must Initiate Clinical
Study of said Licensed Products, and (ii) within [**] months from Initiation of a Pivotal Clinical Study for said Licensed Products,
China Company must submit the relevant application(s) for the Regulatory Approval to Commercialize said Licensed Products. Notwithstanding
the foregoing, the Parties acknowledge and agree that the regulatory process to obtain Regulatory Approval for the Licensed Product
in the China Company Territory has a high level of uncertainty and in the event that the failure to achieve a milestone set forth
in (v), (vi), or (vii) is primarily attributable to regulatory requirements or delays caused by Regulatory Authorities in the China
Company Territory which are out of the control of China Company and which could not reasonably be anticipated as of the Effective
Date (an “Intervening Regulatory Event”), the Parties agree to renegotiate the relevant Milestone Events in good faith
in a manner reasonably taking into consideration the Intervening Regulatory Event.

 

5.      To the last sentence
of Section 4.8.2, the following sentence is added: “Prior to the initiation of clinical trials by China Company, the
Parties will develop and agree in writing to a Quality Agreement (“Quality Agreement”).”

 

Similarly, Schedule F is amended with regard to the reporting requirements corresponding
to Section 4.8.2 to require that the Parties will develop and agree in writing upon a Pharmacovigilance Agreement prior to the
initiation of clinical trials by China Company.

 

     

     

    

 

		6.	The following sentence is added to the end of Section 6.2 (Technology Transfer Responsibilities): 

 

The Parties will execute a technology transfer agreement, using good faith efforts
to do so prior to [**].

 

 

		7.	Schedule E (“Technology Transfer Activities”), section entitled “Target Date” is amended to read
in its entirety as follows:

 

Target Date

 

Technology Transfer of the Manual Method and/or Research Technology
Transfer shall commence in [**]. If China Company chooses to proceed with Technology Transfer of the Automated Systems, China Company
shall send written notice to Argos when Technology Transfer is practicable following the successful production of at least five
batches of Licensed Product at Argos’ principal manufacturing facility for North America (currently in Durham, North Carolina)
and the filing of an amendment to Argos’ BLA for AGS-003 to include manufacture using the Automated Systems.

 

 

All other terms and conditions will remain the same.

 

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their
duly authorized corporate officers or representatives as of the Effective Date of this Amendment.

 

	Argos Therapeutics, Inc.	 	Lummy (Hong Kong) Co., Ltd.
	 	 	 	 	 	 
	By:	/s/Jeff Abbey	 	By:	/s/ Xuefeng Leng	 
	 	 	 	 	 	 
	Name:	Jeff Abbey	 	Name:	Xuefeng Leng	 
	 	 	 	 	 	 
	Title:	President and CEO	 	Title:	DirectorExhibit 10.7

 

LEASE TERMINATION AGREEMENT 

THIS LEASE TERMINATION AGREEMENT (this "Agreement")
is entered into effective March 31, 2017, by and between Keystone-Centennial II, LLC, a North Carolina limited liability
company, ("Landlord"), and Argos Therapeutics, Inc., a Delaware corporation, ("Tenant").

 

RECITALS

 

Pursuant to that Lease Agreement dated January 17, 2017, entered
into by Tenant and Landlord (the "Lease"), Tenant leased from Landlord approximately 40,420 rentable sq.
ft. in that building located at 1010 Main Campus Dr. in Raleigh, NC and identified as the "Center for Technology and Innovation",
(the "Premises"). (The Lease is incorporated into this Agreement by this reference and, except where
specifically provided to the contrary in this document, the capitalized terms shall have the same meaning as those used in the
Lease.) Pursuant to Section 6.1 of the Lease, Tenant delivered a $2,400,000 "Irrevocable Standby Letter of Credit",
dated January 18, 2017, (No. IS0485461U) issued by Wells Fargo Bank, National Association in favor of Landlord (the "Letter
of Credit") to Landlord as security for Tenant's obligations under the Lease. Tenant defaulted under the Lease ("Tenant's
Default") and on March 16, 2017, advised Landlord: (i) that Tenant wanted to terminate the Lease; (ii) that Tenant
was relinquishing all rights to possession of the Premises; and (iii) to begin efforts to relet the Premises. Landlord sent a notice
of termination of Lease to Tenant on March 17, 2017. After negotiation, the parties have agreed to an early termination of the
Lease on the terms and conditions set out below. In consideration of these Recitals and the promises of set out below, the parties
agree as follows:

 

1. TERMINATION/RELEASE. The Lease shall be deemed terminated
as of March 17, 2017 (the "Termination Date"). Notwithstanding Section 30 of the Lease to the contrary,
except for their respective obligations under this Agreement: (i) neither party shall have any further rights or obligations under
the Lease, and (ii) each party releases the other from any and all other claims it may have as against the other arising out of
or relating to the Lease or the Premises, whether those claims are known or not or accrued or not, and whether those claims are
contingent or non-contingent, liquidated, or unliquidated.

 

2. LANDLORD DAMAGES. The parties acknowledge that Landlord
has and will suffer significant damages as a result of Tenant's Default (collectively, the "Landlord Damages"), including
the following:

 

2.1. Construction Costs.  Pursuant to Section 7.2 of
the Lease, Landlord had commenced construction of the Tenant Upfit, which was to be constructed at Tenant's sole cost and expense.
On or about February 22, 2017, Tenant requested that Landlord stop construction of the Tenant Upfit, which it did. As of that date,
Landlord had incurred a total of approximately $748,560 in construction costs in constructing the Tenant Upfit (the "Construction
Costs"). Landlord has demanded payment of the Construction Costs from Tenant; but Tenant has failed to reimburse Landlord
for all but $64,152.70 of the Construction Costs (the "Tenant CC Payment"). Tenant acknowledges that its
obligation to reimburse Landlord for the Construction Costs: (i) is independent of its obligation under the Lease to pay the Rent
to Landlord; and (ii) would exist even if the Lease were not being terminated. Landlord acknowledges that it should be able to
salvage some of the Tenant Upfit which has been completed and, in consideration for such, has agreed to return the Tenant CC Payment
to Tenant.

 

     

     

    

2.2. Lost Rents & Other Damages. Pursuant to Section
17.2 of the Lease, Landlord is entitled to recover from Tenant: (i) any and all commercially reasonable costs (i.e., broker commissions,
alteration/repair costs, attorneys' fees, etc.) incurred by Landlord in reletting the Premises; (ii) any deficiency between Tenant's
scheduled Rent (i.e., Base Rent and Additional Rent) for the remainder of the Term and the rent charged to the new tenant; (iii)
the unamortized portion of the funded Tenant Upfit Allowance; (iv) the Rent Abatement; (v) interest at 12% per annum on all sums
due from Tenant; and (vi) all attorneys' fees incurred by Landlord in enforcing the Lease, (collectively, the "Termination
Damages"). Landlord has begun the reletting process; but, as of yet, has been unable to relet any of the Premises.
Because the Premises has not yet been relet, the parties acknowledge that it is not possible, with any certainty, to calculate
the actual amount of the Termination Damages. The parties have nevertheless agreed that the rent reserved under the Lease for 15%
of the remainder of the Term would not be less than $1,800,000.00. Acknowledging that the Termination Damages are somewhat speculative
and that this Agreement contemplates that the Termination Damages shall be paid in one lump sum (as opposed to over time as contemplated
by the Lease), Landlord has agreed to accept the sum of $1,615,590.00 as payment, in full, of the Termination Damages, payable
solely from the Second Draw (defined below).

 

3. LETTER OF CREDIT. Landlord has previously made a $698,247.86
draw on the Letter of Credit (the "First Draw") in partial payment of the Landlord Damages. Promptly after
the execution and delivery of this Agreement by both parties, Landlord will make a second and final draw on the Letter of Credit
in the amount of $1,665,902.14 (the "Second Draw"), which Landlord will accept as full payment of the balance
of the Landlord Damages due. Promptly after its receipt of the funds from the Second Draw, Landlord shall: (i) have no further
rights to draw on the Letter of Credit; and (ii) return the original Letter of Credit, along with a check for the Tenant CC Payment,
to Tenant. Tenant irrevocably waives any and all rights to contest Landlord's making of either the First Draw or the Second Draw.

 

4. SURVIVING OBLIGATIONS. Notwithstanding the termination
of the Lease, each party's indemnification obligations under Section 27 of the Lease with respect to broker's commissions shall
remain in full force and effect and shall survive this termination of the Lease.

 

5. REPRESENTATIONS. Each party warrants that: (i) it is authorized
and empowered to enter into this Agreement; (ii) the person signing in a representative capacity on its behalf is duly authorized
to sign this Agreement; and (iii) this Agreement constitutes its valid and binding obligation and is enforceable against it in
accordance with its terms.

 

6. MISCELLANEOUS. This Agreement constitutes the entire agreement
between the parties on the subject of the termination of the Lease. All of the parties' prior agreements on this subject, whether
oral or written, shall be of no force and effect. This Agreement cannot be modified other than by an agreement in writing signed
by both parties. This Agreement shall be binding upon each party’s successors and assigns. Except as except as expressly
provided otherwise in this Section, Sections 1.2, 26, 31.6, 31.7, 31.8, and 31.9 of the Lease shall be applicable to this Agreement
and references in those Sections to "Lease" shall be construed to refer to this Agreement. The parties have
executed this Agreement as an accord and satisfaction.

 

 

[Signatures on Next Two Pages]

 

 

     

     

    

IN WITNESS WHEREOF, the undersigned have caused this Agreement
to be executed and delivered all on the date first above written.

 

 

LANDLORD:

 

Keystone-Centennial II, LLC,

a North Carolina limited liability company

 

By Its Manager:

Keystone Corporation,

a North Carolina corporation

 

 

By: /s/ J. Patrick Gavaghan (SEAL)

Name: J. Patrick Gavaghan

Title: President

 

 

 

 

 

 

 

 

 

 

     

     

    

TENANT:

 

Argos Therapeutics, Inc.,

a Delaware corporation

 

 

 

By: /s/ Jeffrey D. Abbey

Name/Title: Jeffrey D. Abbey, CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00270-of-00352.parquet"}]]